Alembic Pharma gets tentative USFDA nod for cancer drug Ivosidenib Ruchika Sharma5 July 2024 5:45 AMVadodara: Alembic Pharmaceuticals Limited has announced that the Company has received tentative approval from the US Food & Drug...
Incretin-based diabetes drugs don't increase cholangiocarcinoma risk: Study Medha Baranwal14 Oct 2021 4:45 AMSweden: A recent study using nationwide data from three countries found the use of DPP4 inhibitors and GLP-1-receptor agonists to be not associated...
Long term use of PPIs Increase the Risk of Biliary Tract Cancer: Study MD Bureau1 Jun 2021 3:15 AMBiliary tract cancer is a heterogeneous group of aggressive malignant disorders constituting ~3% of all gastrointestinal malignancies. In a recent...
Metformin and Vitamin D Improve Clinical Outcomes of Cholangiocarcinoma: Study MD Bureau1 March 2021 12:15 AMCholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common hepatic malignancy after hepatocellular carcinoma (HCC). A...
FDA approves pemigatinib as first treatment for advanced cholangiocarcinoma Dr. Kamal Kant Kohli18 April 2020 3:11 AMThe U.S. Food and Drug Administration has approved pemigatinib as first treatment for adults with certain types of previously treated, advanced...
